-
Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply
•
Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical have entered into a significant technology transfer, manufacturing, and clinical supply service agreement with Swiss pharmaceutical giant Novartis (NYSE: NVS). The agreement pertains to the co-developed CAR-T cell therapy, Carvykti (ciltacabtagene autoleucel; cilta-cel), and is…
-
CanSino Biologics Receives NMPA Approval for Bivalent COVID-19 mRNA Vaccine
•
CanSino Biologics Inc., a leading Chinese vaccines specialist, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative bivalent COVID-19 mRNA vaccine. This development signifies a significant step forward in the company’s efforts to combat the evolving SARS-CoV-2 virus. Preclinical Study…
-
JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC
•
JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed in a Phase Ib clinical study for its small-molecule aurora A kinase (AURKA) inhibitor, VIC-1911. This trial marks a significant step in the development of the drug, which is being investigated for its potential in…
-
Simcere Pharmaceutical Group Reports 26.4% YOY Revenue Growth in 2022 Financials
•
Simcere Pharmaceutical Group (HKG: 2096), a China-based pharmaceutical company, has reported its financial results for the year 2022, showcasing a significant increase in revenues. The company recorded RMB 6.139 billion (USD 920 million) in revenues, marking a 26.4% year-on-year (YOY) growth. Revenue Breakdown and R&D InvestmentRevenues from the innovative medicine…
-
Henlius Reports 97.2% YOY Revenue Growth in Q1 2023, Highlighted by Strong Sales of Hanquyou and HaiSiZhuang
•
China-based biopharmaceutical company Henlius (HKG: 2696) has released its financial report for the first quarter of 2023, showing a robust increase in revenues. As of March 31, 2023, the company reported revenues of RMB 995.7 million (USD 144.9 million), marking a 97.2% year-on-year (YOY) growth. Sales Performance of Key ProductsHenlius’s…
-
Minghui Pharmaceutical’s MH004 Cream Shows Positive Results in Atopic Dermatitis Phase II Trial
•
China-based Minghui Pharmaceutical has unveiled positive top-line data from a Phase II trial of its MH004 cream, which is being evaluated as a treatment for adolescents and adults with mild-to-moderate atopic dermatitis (AD). The cream, a pan-JAK inhibitor, successfully met its primary endpoint and all key secondary endpoints, demonstrating its…
-
AffaMed Therapeutics Gets NMPA Approval for Phase III Dextenza Study in Post-Ophthalmic Surgery
•
China-based AffaMed Therapeutics has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase III regulatory study. The study will assess the efficacy and safety of Dextenza in subjects following ophthalmic surgery, marking a significant step forward for the company. Dextenza’s Development and…
-
Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023
•
China-based Harbour Biomed (HKG: 2142) is set to release early clinical data for its CTLA-4 antibody in combination with Junshi Biosciences’ (HKG: 1877, SHA: 688180) programmed death-1 (PD-1) inhibitor toripalimab as a treatment for neuroendocrine neoplasms (NENs). The findings will be presented via a poster at the upcoming American Association…
-
RemeGen’s Disitamab Vedotin (RC48) Clears for Phase I Study in HER2-Positive Tumors
•
RemeGen Ltd (HKG: 9995), a biopharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study for its antibody-drug conjugate (ADC) candidate, disitamab vedotin (RC48). This single-arm, open, single-center study aims to evaluate the safety and maximum tolerable…
-
Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for JS401, an injectable co-developed with Risen Pharma, for the treatment of hyperlipidemia. JS401’s Mechanism of ActionJS401 is an innovative angiopoietin-like 3 (ANGPTL3)…
-
Jiangxi Jemincare Group Secures Exclusive Rights to Promote MabPharm’s Biosimilar CMAB007
•
Jiangxi Jemincare Group, a China-based healthcare company, has entered into a licensing agreement with fellow Chinese firm MabPharm Ltd (HKG: 2181) to obtain exclusive promotion rights to CMAB007, a prospective biosimilar of Roche/Genentech’s anti-IgE drug omalizumab, known under the trade name Xolair. The agreement encompasses rights across Greater China, including…
-
Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China, has entered into a strategic partnership with Meituan, the country’s leading delivery giant, to explore new digital and intelligent medical and healthcare service models. The collaboration aims to leverage the strengths of both companies to…
-
Ocumension Therapeutics’ Zerviate NDA Accepted for Review by China’s NMPA
•
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that the National Medical Products Administration (NMPA) has accepted for review the New Drug Application (NDA) for Zerviate (OT-1001), a histamine H1 receptor-targeted therapy. This development marks a significant step forward for the company in bringing this innovative treatment…
-
Pfizer and Sinopharm Expand Partnership to Enhance Drug Distribution and Lifecycle Solutions
•
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced a strategic partnership with China-based Sinopharm Group Co., Ltd (HKG: 1099). This collaboration expands on their existing relationship, which spans several years and includes activities in importing, distribution, outsourcing, retailing, and other areas. The partnership aims to leverage Sinopharm’s extensive logistics…
-
Fosun Pharmaceutical’s FCN-159 Earns Breakthrough Therapy Designation for Histiocyte Tumors
•
The Center for Drug Evaluation (CDE) website has announced that Shanghai Fosun Pharmaceutical (Group) Co., Ltd’s (SHA: 600196, HKG: 2196) novel small-molecule chemical drug FCN-159 has been granted breakthrough therapy designation (BTD) status for the treatment of histiocyte tumors. FCN-159’s Mechanism and ImpactFCN-159 is a highly selective MEK1/2 inhibitor with…
-
Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the National Medical Products Administration (NMPA) has accepted for review its clinical trial approval filing for ASKC200, a liniment product in-licensed from US-based Propella Therapeutics, Inc. The primary indication for the product is the treatment of osteoarthritis pain. Product Rights…
-
HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency
•
HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the field of CRISPR-Cas genome editing technology. Through protein and sgRNA engineering, HuidaGene has enhanced the OsCas12f1 (enOsCas12f1) and enRhCas12f1 variants of the CRISPR-Cas12f system. These variants exhibit much higher editing efficiency and possess broader PAMs…
-
Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion
•
PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed for an initial public offering (IPO) with the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The company anticipates raising RMB 601 million (USD 87.8 million) in proceeds, which will be allocated towards the construction of…
-
Huadong Medicine Reports 9.12% YOY Revenue Growth and 13.24% Increase in Net Profits for 2022
•
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has released its 2022 financial report, demonstrating robust growth with revenues of RMB 37.715 billion (USD 5.5 billion), an increase of 9.12% year-on-year (YOY), and net profits of RMB 2.598 billion (USD 379.3 million), marking a 13.24% YOY increase.…
-
BeiGene Launches LATAM Expansion with New Office in São Paulo, Brazil
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced its first major step in expanding its presence in Latin America (LATAM) with the formal opening of its office in São Paulo, Brazil. This strategic move positions BeiGene to tap into the largest oncology market in the…
